AJP - Heart AJP: Lung Cellular and Molecular Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 289: H898-H907, 2005. First published March 25, 2005; doi:10.1152/ajpheart.00883.2003
0363-6135/05 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
289/2/H898    most recent
00883.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Phillipson, A.
Right arrow Articles by Young, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Phillipson, A.
Right arrow Articles by Young, L. H.

Protein kinase C-{zeta} inhibition exerts cardioprotective effects in ischemia-reperfusion injury

Aisha Phillipson, Ellen E. Peterman, Philip Taormina, Jr., Margaret Harvey, Richard J. Brue, Norrell Atkinson, Didi Omiyi, Uchenna Chukwu, and Lindon H. Young

Department of Pathology, Microbiology, and Immunology, Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania

Submitted 15 September 2003 ; accepted in final form 4 February 2005


   ABSTRACT
TOP
 ABSTRACT
METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Ischemia followed by reperfusion (I/R) in the presence of polymorphonuclear leukocytes (PMNs) results in marked cardiac contractile dysfunction. A cell-permeable PKC-{zeta} peptide inhibitor was used to test the hypothesis that PKC-{zeta} inhibition could attenuate PMN-induced cardiac contractile dysfunction by suppression of superoxide production from PMNs and increase nitric oxide (NO) release from vascular endothelium. The effects of the PKC-{zeta} peptide inhibitor were examined in isolated ischemic (20 min) and reperfused (45 min) rat hearts reperfused with PMNs. The PKC-{zeta} inhibitor (2.5 or 5 µM, n = 6) significantly attenuated PMN-induced cardiac dysfunction compared with I/R hearts (n = 6) receiving PMNs alone in left ventricular developed pressure (LVDP) and the maximal rate of LVDP (+dP/dtmax) cardiac function indexes (P < 0.01), and these cardioprotective effects were blocked by the NO synthase inhibitor, NG-nitro-L-arginine methyl ester (50 µM). Furthermore, the PKC-{zeta} inhibitor significantly increased endothelial NO release 47 ± 2% (2.5 µM, P < 0.05) and 54 ± 5% (5 µM, P < 0.01) over basal values from the rat aorta and significantly inhibited superoxide release from phorbol-12-myristate-13-acetate-stimulated rat PMNs by 33 ± 12% (2.5 µM) and 40 ± 8% (5 µM) (P < 0.01). The PKC-{zeta} inhibitor significantly attenuated PMN infiltration into the myocardium by 46–48 ± 4% (P < 0.01) at 2.5 and 5 µM, respectively. In conclusion, these results suggest that the PKC-{zeta} peptide inhibitor attenuates PMN-induced post-I/R cardiac contractile dysfunction by increasing endothelial NO release and by inhibiting superoxide release from PMNs thereby attenuating PMN infiltration into I/R myocardium.

neutrophils; superoxide radicals; left ventricular developed pressure; endothelial dysfunction

THE RESTORATION OF BLOOD FLOW is the primary objective for treatment of cardiac tissue experiencing prolonged ischemia (i.e., >20 min). However, reperfusion of blood flow induces endothelium and myocyte injury, resulting in cardiac contractile dysfunction (4, 23, 24). The sequential events associated with reperfusion injury are initiated by endothelial dysfunction, which is characterized by a reduction of the basal endothelial cell release of nitric oxide (NO) within the first 2.5–5 min postreperfusion (36). The decrease in endothelium-derived NO is associated with adhesion molecule upregulation on endothelial and polymorphonuclear leukocyte (PMN) cell membranes (26, 39). This event promotes PMN-endothelium interaction, which occurs by 10 to 20 min postreperfusion, and subsequent PMN infiltration into the myocardium is observed by 30 min postreperfusion (20, 21, 35, 39). The time course of events are similar in ex vivo and in vivo myocardial ischemia-reperfusion (I/R) models within the first 30 min of reperfusion with respect to endothelial dysfunction and PMN-endothelium interactions (26, 35–37). However, the in vivo model requires a longer reperfusion period (i.e., 270 min) to accumulate PMNs in the reperfused myocardium and induce myocardial injury (i.e., infarct size) (26, 35) compared with the ex vivo I/R model, in which PMNs are infused at the beginning of reperfusion and readily accumulate into the myocardium between 30 and 45 min of reperfusion to induce myocardial injury (i.e., sustained cardiac contractile dysfunction) (5, 29, 41–43).

Chemotactic substances released from reperfused tissue and plasma factors activate PMNs that augment PMN release of cytotoxic substances (i.e., superoxide anion) and contribute to cardiac contractile dysfunction after I/R (24, 25, 35, 37). Superoxide combines with NO to produce peroxynitrite anion, thus reducing the bioavailability of NO, and promotes endothelial dysfunction and PMN infiltration after myocardial I/R (6, 13, 24, 31, 37, 38). Likewise, compounds that increase endothelium-derived NO release quench superoxide anion from PMNs and reperfused tissues and inhibit PMN infiltration and preserve cardiac function after I/R (21, 41). These findings suggest that compounds that enhance endothelial NO release or inhibit endothelium-PMN superoxide release may exert cardioprotective effects in I/R injury (29).

Protein kinase C (PKC) is an important cytosolic enzyme involved in the signaling pathway of PMNs and endothelial cells. In PMNs, PKC activation increases superoxide release via phosphorylation of the cytosolic factor p47phox, which is required for NADPH oxidase activation (1, 7, 22, 40). In endothelial cells, PKC activation inhibits endothelial NO synthase (eNOS) activity, resulting in decreased endothelial NO release (14, 30), and augments superoxide and hydrogen peroxide production via NADPH oxidase (44). Consequently, inhibition of PKC leads to enhanced NO bioavailability in endothelial cells by these two mechanisms (41, 42).

PKC exists in different isoforms that are subdivided into three biochemical classes of function (9). The classical isoforms are Ca2+ dependent and activated by diacylglycerol (DAG); the novel isoforms are Ca2+ independent but are activated by DAG; and, finally, the atypical isoforms are Ca2+ and DAG independent (9, 11). Of particular interest is the atypical isoform PKC-{zeta}, which can be stimulated by phospholipids and augments superoxide production in PMNs and endothelial cells and PMN chemotaxis (7, 8, 10, 19). However, the role of PKC-{zeta} in myocardial I/R and endothelial NO release has not been previously characterized.

In this study, the hypothesis tested was that PKC-{zeta} inhibition attenuates PMN-induced cardiac contractile dysfunction and PMN vascular adherence and infiltration in postreperfused hearts. In addition, the hypothesis predicted that PKC-{zeta} inhibition attenuates PMN superoxide release and augments endothelial NO release. The selective PKC-{zeta} peptide inhibitor used in these assays was myristoylated (fatty acid moiety) to allow for rapid cell permeability (within 10 s) and was 13 amino acids in length (N-myristoyl-SIYRRGARRWRKL, mol wt = 1,928, Genemed Synthesis). The peptide sequence corresponds to positions 113–125 of the pseudosubstrate domain on PKC-{zeta}, thereby inhibiting PKC-{zeta} from interacting with other cellular substrates (i.e., NADPH oxidase) (7, 19). Dang et al. (7) observed an IC50 equal to ~10 µM with respect to inhibition of PMN superoxide release.


   METHODS
TOP
 ABSTRACT
 METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Isolated Rat Heart Preparation

The Institutional Animal Care and Use Committee of Philadelphia College of Osteopathic Medicine approved all animal protocols performed in this study. Male Sprague-Dawley rats (275–325 g, Ace Animals; Boyertown, PA) were anesthetized with 60 mg/kg pentobarbital sodium intraperitoneally. Heparin sodium (1,000 units) was also administered intraperitoneally. The hearts were rapidly excised, the ascending aortas were cannulated, and retrograde perfusion of the heart was initiated with a modified Krebs buffer maintained at 37°C at a constant pressure of 80 mmHg. The Krebs buffer had the following composition (in mmol/l): 17 dextrose, 120 NaCl, 25 NaHCO3, 2.5 CaCl2, 0.5 EDTA, 5.9 KCl, and 1.2 MgCl2. The perfusate was aerated with 95% O2-5% CO2 and equilibrated at a pH of 7.3–7.4. The two side arms in the perfusion line proximal to the heart inflow cannula allowed PMNs, plasma without PKC-{zeta} peptide inhibitor (control hearts), or plasma containing different concentrations of PKC-{zeta} peptide inhibitor (1, 2.5, or 5 µM) to be directly infused into the coronary inflow line. Coronary flow was monitored by a flowmeter (T106, Transonic Systems; Ithaca, NY). Left ventricular developed pressure (LVDP) and the maximal rate of LVDP (+dP/dtmax) were monitored using a pressure transducer (SPR-524, Millar Instruments; Houston, TX), which was positioned in the left ventricular cavity. Hearts were immersed in a water-jacketed reservoir containing 160 ml Krebs buffer maintained at 37°C. Coronary flow, LVDP, and +dP/dtmax were recorded using a Powerlab Station acquisition system (ADInstruments; Grand Junction, CO) in conjunction with a computer (Gateway).

LVDP, +dP/dtmax, and coronary flow were measured every 5 min for 15 min to equilibrate the hearts and obtain a baseline measurement. LVDP was defined as left ventricular end-systolic pressure minus left ventricular end-diastolic pressure.

After 15 min, the flow of the Krebs buffer was reduced to zero for 20 min to induce global ischemia. At reperfusion, hearts were infused for 5 min with 200 x 106 PMNs resuspended in 5 ml Krebs buffer plus 5 ml plasma at a rate of 1 ml/min. In some experiments, the PKC-{zeta} peptide inhibitor (Genemed Synthesis) was added to plasma at a final concentration of 1, 2.5, or 5 µM. Sham I/R hearts were not subjected to ischemia and were not perfused with PMNs. We (29) recently showed that sham I/R hearts given PMNs exhibited no changes from initial control values.

Groups of Isolated Perfused Hearts

The following groups of isolated perfused rat hearts were used.

Group 1. Sham I/R hearts were not subjected to ischemia and were not perfused with PMNs but were perfused with 5 ml plasma (1 ml/min) at 35 min into perfusion (the same time point that I/R hearts would be given 5 ml plasma, 15 min of baseline recordings plus 20 min ischemia). These hearts represented a control group to determine whether the isolated rat heart could maintain LVDP and +dP/dtmax throughout the 80-min protocol (n = 6).

Group 2. Sham I/R + PKC-{zeta} peptide inhibitor (5 µM) hearts were not subjected to ischemia and not perfused with PMNs. These hearts were administered the PKC-{zeta} peptide inhibitor (5 µM, dissolved in plasma from a 5 mM stock in H2O) 35 min into perfusion. This group was employed to determine whether the PKC-{zeta} peptide inhibitor causes a cardiotonic or cardiodepressant effect (n = 6).

Group 3. I/R hearts were subjected to 20 min of ischemia and were perfused with 5 ml plasma (1 ml/min) during the first 5 min of reperfusion but were not perfused with PMNs. These hearts represented a control group to determine whether 20 min of ischemia followed by reperfusion stuns the heart but whether LVDP and +dP/dtmax would recover to baseline values (initial) by the end of the 45-min reperfusion period (n = 6).

Group 4. I/R + PKC-{zeta} peptide inhibitor (5 µM, dissolved in plasma) hearts were subjected to 20 min of ischemia and were not perfused with PMNs. These hearts are perfused with 5 ml plasma + PKC-{zeta} inhibitor during the first 5 min of reperfusion. This group was employed to determine whether the PKC-{zeta} peptide inhibitor causes a cardiodepressant effect in the setting of I/R without PMNs (n = 6).

Group 5. I/R + PMN hearts were subjected to 20 min of ischemia and were perfused with 5 ml plasma (1 ml/min) and PMNs (resuspended in 5 ml Krebs buffer) during the first 5 min of reperfusion. These hearts represented a control group to determine whether 20 min of ischemia followed by 45 min reperfusion in the presence of PMNs (200 x 106) results in a sustained cardiac contractile dysfunction throughout the 45-min reperfusion period compared with initial baseline values (5, 29, 41–43) (n = 6).

Group 6. I/R + PMN + PKC-{zeta} peptide inhibitor (1 µM) hearts were subjected to 20 min of ischemia and were perfused with 1 µM PKC-{zeta} peptide inhibitor (dissolved in plasma) and PMNs (200 x 106) during the first 5 min of reperfusion. These hearts represented a group to determine the effect of PKC-{zeta} inhibition in attenuating PMN-induced cardiac contractile dysfunction (n = 6).

Group 7. I/R + PMN + PKC-{zeta} peptide inhibitor (2.5 µM) hearts were subjected to 20 min of ischemia and were perfused with 2.5 µM PKC-{zeta} peptide inhibitor (dissolved in plasma) and PMNs (200 x 106) during the first 5 min of reperfusion. These hearts represented a group to determine the effect of PKC-{zeta} inhibition in attenuating PMN-induced cardiac contractile dysfunction (n = 6).

Group 8. I/R + PMN + PKC-{zeta} peptide inhibitor (5 µM) hearts were subjected to 20 min of ischemia and were perfused with 5 µM PKC-{zeta} peptide inhibitor (dissolved in plasma) and PMNs (200 x 106) during the first 5 min of reperfusion. These hearts represented a group to determine the effect of PKC-{zeta} inhibition at a higher concentration of the PKC-{zeta} peptide inhibitor in attenuating PMN-induced cardiac contractile dysfunction (n = 6).

Group 9. I/R + PMN + PKC-{zeta} peptide inhibitor (5 µM) + NG-nitro-L-arginine methyl ester (L-NAME; 50 µM) hearts were subjected to 20 min of ischemia and were perfused with 5 µM PKC-{zeta} peptide inhibitor (dissolved in 5 ml plasma) and 50 µM L-NAME (dissolved in Krebs buffer from 50 mM stock in H2O) and PMNs (200 x 106) during the first 5 min of reperfusion. L-NAME (50 µM) was continually infused into the heart throughout the 45-min reperfusion period. These hearts represented a group to determine whether the cardioprotective effect of PKC-{zeta} peptide inhibition can be blocked with a NO synthase inhibitor (L-NAME) (n = 5).

Data were recorded every 5 min for 45 min postreperfusion. After each experiment, the left ventricle was isolated, fixed in 4% paraformaldehyde, and stored at 4°C for later histological analysis.

Isolation of Plasma

The plasma used for infusion with the PMNs was isolated from the same rat from which the heart was isolated from for each cardiac perfusion experiment to more closely simulate the conditions in vivo. Blood was collected from the aorta in citrate phosphate buffer (Sigma Chemical; St. Louis, MO) over a period of 1 min just before isolation of the rat heart. The blood was centrifuged at 10,000 g for 10 min at 4°C. The plasma was then decanted and used for infusion in each heart. Five milliliters of plasma collected from a single rat were used for each perfused heart.

Isolation of PMNs

Male Sprague-Dawley rats (350–400 g, Ace Animals), used as PMN donors, were anesthetized with ethyl ether and given a 16 ml ip injection of 0.5% glycogen (Sigma Chemical) dissolved in PBS (42). Rats were reanesthetized with ethyl ether 16–18 h later, and the PMNs were harvested by peritoneal lavage in 30 ml of 0.9% NaCl, as previously described (42). The peritoneal lavage fluid was centrifuged at 250 g for 20 min at 4°C. The PMNs were then washed in 20 ml PBS and centrifuged at 250 g for 10 min at 4°C. Thereafter, the PMNs were resuspended in 2.5 ml PBS, and a total of 10–12 samples was pooled before use in cardiac perfusion experiments. The PMN preparations were >90% pure and >95% viable according to microscopic analysis and exclusion of 0.3% Trypan blue, respectively.

Determination of PMN Vascular Adherence and Infiltration Into Cardiac Tissue

Three rat hearts from each of the nine experimental groups were used for histological analysis. Ten similar areas of each heart section, ranging from the endocardium throughout the myocardium to the epicardium of the left ventricle, were counted for PMN vascular adherence and infiltration. The hearts were dehydrated in graded ice-cold acetone washes (50–100%). The heart tissue was then embedded in plastic, sectioned into 2.5-µm serial sections, and placed onto glass slides. Sections were then placed in 100% ethanol for 5 min to remove the plastic and rehydrated in tap water for 1 min. Subsequently, hematoxylin was applied to the sections for 7 min, and the sections were rinsed under running tap water for 30 s. Eosin stain was then applied for 2 min, followed by a second rinse under running tap water for 30 s. The number of PMNs was counted by light microscopy (41, 42). To determine the effect of the PKC-{zeta} peptide inhibitor on PMN adherence, the intravascular PMNs that adhered to the lumen of the coronary vascular endothelium were counted and expressed as adhered intravascular PMNs per millimeter squared. The total amount of PMNs counted within the heart tissue sections is expressed as total intravascular and infiltrated PMNs per millimeter squared area of cardiac tissue.

Measurement of NO Release From Rat Aortic Segments

Rat aortas were isolated after the rats were anesthetized with pentobarbital sodium (60 mg/kg). The excised aortas were immersed in warm oxygenated (95% O2-5% CO2) Krebs-Henselit (K-H) buffer solution. The K-H buffer had the following composition (in mmol/l): 10 dextrose, 119 NaCl, 12.5 NaHCO3, 2.5 CaCl2, 4.8 KCl, 1.2 KH2PO4, and 1.2 MgSO4. The aortas were cleaned of adherent fat and connective tissue, and rings 6–7 mm long (i.e., 10 mg wet wt) were prepared. The aortic rings were cut, spread opened, and fixed by pins with the endothelial surface facing up in 24-well culture dishes containing 1 ml K-H solution (41). In other aortic segments, the endothelium was removed (denuded) from the vascular smooth muscle using mechanical isolation with a cotton swab to determine the source of NO release. After equilibration at 37°C, NO released into the buffer solution was measured after the administration of PKC-{zeta} peptide inhibitor (1–15 µM) to the aortic rings. Acetylcholine (200 nM) was used as a positive control to assess the viability of the endothelium. Basal rat aortic endothelial NO release was determined by placing the NO electrode in a well containing only K-H buffer and then placing the NO electrode in a well containing aortic tissue. The difference between the two readings determined the basal NO release for that aortic endothelial segment (41). After basal NO release, the effect of acetylcholine (200 nM) and PKC-{zeta} peptide inhibitor were determined, 400 µM L-NAME was added to the K-H buffer solution, and NO release was reassessed 30 min later in the presence of acetylcholine (200 nM) or PKC-{zeta} peptide (5 µM) inhibitor. The NO release was measured using a calibrated NO meter (Iso-NO, World Precision Instruments; Sarasota, FL) connected to a polygraph internally shielded NO electrode (12, 41). NO released into the medium was reported in picomoles per milligram of aortic tissue. Between 6 and 20 trials were performed for each group.

Measurement of Superoxide Radical Release From Rat PMNs

The superoxide anion release from PMNs was measured spectrophotometrically (model 260 Gilford, Nova Biotech; El Cajon, CA) by the reduction of ferricytochrome c (42). The PMNs (5 x 106) were resuspended in 450 µl PBS and incubated with ferricytochrome c (100 µM, Sigma Chemical) in a total volume of 900 µl PBS for 15 min at 37°C in spectrophotometric cells. PKC-{zeta} peptide inhibitor was added to the 900 µl PMN-ferricytochrome c suspension, mildly vortexed to yield a final concentration of 1, 2.5, 5, or 15 µM, and incubated at 37°C for 15 min in spectrophotometric cells. Control samples did not contain PKC-{zeta} peptide inhibitor. The PMNs were stimulated with 15 nM phorbol-12-myristate-13-acetate (PMA; Sigma Chemical) in a final reaction volume of 1.0 ml. Positive control samples were given superoxide dismutase (SOD; 10 µg/ml) just before the addition of PMA. Absorbance at 550 nm was measured every 30 s for up to 360 s (peak response), and the change ({Delta}) in superoxide anion release from PMNs was determined from time 0.

Limitations of the Study

A latex balloon was not inserted into the left ventricle, and therefore this study does not have a fixed preload volume as in other ex vivo isolated perfused rat heart studies using a similar protocol of 20-min global ischemia and 45-min reperfusion (16, 33). This limitation should be taken into consideration when the data are interpreted. However, the animals that were used in this study were within a specific weight range (275–325 g) for each group, and the initial baseline LVDP and +dP/dtmax values were similar among all of the study groups, and so therefore there should be similar preloads. The isolated rat heart was cannulated via the aorta onto a perfusion needle and was immersed in a water-jacketed reservoir that contained 160 ml Krebs buffer maintained at 37°C. The preload volume comes from Krebs buffer that fills the left ventricle upon insertion of the pressure transducer catheter via a small incision (i.e., 1 mm) in the base of the left side of the heart as in previous studies (41–43). The initial baseline left ventricular end-diastolic pressure was between 4 and 8 mmHg for all hearts in each study group. In the event that a procedural mistake was made and the perfusion needle penetrated the aortic valve, the heart experienced an increase in diastolic pressure (i.e., above 8 mmHg) accompanied by arrhythmia within 5 min of perfusion. The preparation was therefore discarded and not included in any analyses.

This ex vivo myocardial I/R model was designed for PMN-induced myocardial I/R injury and differed from the in vivo model, which requires 90 min of ischemia (left anterior descending coronary artery occlusion) followed by 270-min reperfusion before significant PMN infiltration in postreperfused myocardial tissue is observed (35, 42). The ex vivo model was intended to evaluate compounds that have the potential to attenuate PMN-induced myocardial I/R injury.

The aortic tissue NO release and PMN superoxide release are in vitro assays that may not be physiologically relevant to in vivo conditions. The results obtained from these assays were intended to suggest a NO and/or superoxide mechanism by which the PKC-{zeta} peptide inhibitor may exert its cardioprotective effects.

Statistical Analysis

All data in the text and figures are presented as means ± SE. The data were analyzed by ANOVA using post hoc analysis with the Bonferroni/Dunn test. Probability values of <0.05 were considered to be statistically significant.

On the basis of the number of planned groups for comparison coupled with the realistic constraints regarding the number of hearts that could be evaluated, it is recognized that a very strong effect is required to achieve statistical significance. Depending on the number of hearts and groups being compared, effect sizes between 2.5 and 3.2 are required to achieve statistical significance.


   RESULTS
TOP
 ABSTRACT
 METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
The time course of cardiac contractile function (i.e., LVDP) is shown in Figure 1. Data from the sham I/R, I/R, I/R + PMN + PKC-{zeta} peptide inhibitor (5 µM), and I/R + PMN groups illustrate the relative changes in LVDP during the 80-min perfusion period. As shown, the sham I/R group remained near or >100% of initial baseline values of LVDP for the entire perfusion period. The I/R hearts experienced a depression in LVDP at the beginning of reperfusion but recovered to 95 ± 7% of initial baseline values by the end of reperfusion. In contrast, the I/R + PMN hearts suffered severe cardiac contractile dysfunction, recovering to only 47 ± 7% of initial baseline values by 45 min postreperfusion. Conversely, the I/R + PMN + PKC-{zeta} peptide inhibitor (5 µM) hearts recovered to 84 ± 4% at 45 min postreperfusion.



View larger version (18K):
[in this window]
[in a new window]
  		Fig. 1. Time course of left ventricular developed pressure (LVDP) in sham, ischemia-reperfusion (I/R), I/R + polymorphonuclear neutrophils (PMN), and I/R + PMN + PKC-{zeta} peptide inhibitor (5 µM) perfused rat hearts. LVDP data at initial (baseline) and reperfusion from 0 to 45 min after 20-min ischemia are shown. The sham group (n = 6) maintained the same LVDP throughout the 80-min protocol. The I/R (n = 6) group recovered to initial baseline baseline values. The I/R + PMN group (n = 6) exhibited a significant and sustained reduction in LVDP compared with the I/R + PMN + PKC-{zeta} peptide inhibitor group (n = 6). All values are expressed as means ± SE. *P < 0.05 and **P < 0.01, I/R + PMN + PKC-{zeta} peptide inhibitor group compared with the I/R + PMN group.

 
To determine whether PKC-{zeta} peptide inhibitor produced direct inotropic effects on cardiac contractile function, nonischemic sham I/R hearts were perfused with the PKC-{zeta} peptide inhibitor (5 µM). Treatment of sham I/R hearts with PKC-{zeta} peptide inhibitor did not result in any significant change in LVDP (Fig. 2) or +dP/dtmax (Fig. 3) during the 80-min perfusion period, demonstrating the PKC-{zeta} peptide inhibitor at 5 µM exerts no direct effect on cardiac contractile function. A 15 µM PKC-{zeta} peptide inhibitor concentration was initially tested because this concentration corresponded with an 82% inhibition of PMN superoxide release. However, 15 µM produced a cardiodepressant effect (50% reduction in LVDP in sham I/R hearts) and could not be used in these experiments (data not shown).



View larger version (29K):
[in this window]
[in a new window]
  		Fig. 2. Initial and final LVDP (expressed in mmHg) from isolated perfused rat hearts before ischemia (I; initial) and after 45-min postreperfusion (R; final). Hearts were perfused in the presence or absence or PMNs. PMNs induced a significant contractile dysfunction, which was attenuated by the PKC-{zeta} peptide inhibitor but was not significantly blocked by NG-nitro-L-arginine methyl ester (L-NAME). All values are expressed as means ± SE. Numbers of hearts are shown at the bottom of the bars. NS, not significant. **P < 0.01 from final I/R + PMN.

 


View larger version (26K):
[in this window]
[in a new window]
  		Fig. 3. Initial and final maximal rate of LVDP (+dP/dtmax, expressed in mmHg/s) in isolated perfused rat hearts before ischemia and after reperfusion. Hearts were perfused in the presence or absence of PMNs. PMNs induced a significant contractile dysfunction, which was attenuated by the PKC-{zeta} peptide inhibitor but was blocked by L-NAME. All values are expressed as means ± SE. Numbers of hearts are shown at the bottom of the bars. **P < 0.01 from final I/R + PMN.

 
Figures 2 and 3 show the initial and final values for LVDP and +dP/dtmax from isolated perfused rat hearts. The initial baselines were similar for all groups. However, the final LVDP and +dP/dtmax (45 min postreperfusion) were significantly decreased (P < 0.01) by 47 ± 7% and 41 ± 7%, respectively, for I/R hearts reperfused with PMNs compared with initial baseline values. The PKC-{zeta} peptide inhibitor (2.5 and 5 µM concentrations) significantly attenuated the decrease in LVDP and +dP/dtmax associated with postischemic reperfusion with PMNs. In the group receiving 5 µM of drug, hearts recovered to 84 ± 4% and 76 ± 5% for final LVDP and +dP/dtmax compared with initial baseline values. The lowest effective dose was observed at 2.5 µM, and these hearts recovered to 83 ± 4% for LVDP and 75 ± 5% for +dP/dtmax compared with initial baseline values. The cardioprotective effects of the PKC-{zeta} peptide inhibitor (5 µM) were blocked in the presence of L-NAME (50 µM). These hearts only recovered to 58 ± 7% and 54 ± 9% for LVDP and +dP/dtmax, respectively, at 45 min postreperfusion compared with initial baseline values. These hearts were similar to the IR + PMN group (47 ± 7% and 41 ± 7% LVDP and +dP/dtmax). At 1 µM, PKC-{zeta} peptide inhibitor-treated hearts exposed to I/R + PMNs only recovered to 57 ± 10% and 46 ± 6% for LVDP and +dP/dtmax, respectively, at 45 min postreperfusion compared with initial baseline values. These hearts were not significantly different from control I/R + PMN hearts at 45 min postreperfusion at this lower dose.

The cardiac injury associated with I/R in this model was closely correlated with the substantial number of PMNs infiltrating the myocardium within the 45-min reperfusion period. During reperfusion, a significant number of PMNs transmigrated into the myocardium, increasing from <25 PMNs/mm2 in sham I/R hearts to >180 PMNs/mm2 in I/R + PMN hearts at the end of the reperfusion period (Fig. 4A). In contrast, I/R + PMN + PKC-{zeta} peptide inhibitor-treated hearts experienced a 20 ± 6%, 46 ± 4%, and 48 ± 3% significant reduction in PMN infiltration into the postreperfused cardiac tissue at 1, 2.5, and 5 µM (P < 0.01), respectively, and this effect was blocked in the presence of L-NAME. Furthermore, the 2.5 and 5 µM-treated hearts had significantly fewer infiltrated PMNs compared with 1 µM-treated hearts (P < 0.01; Fig. 4A).



View larger version (18K):
[in this window]
[in a new window]
  		Fig. 4. A: histological assessment of total intravascular and infiltrated PMNs in isolated perfused rat heart samples taken from 3 rats/group and 10 areas/heart. The numbers of total intravascular and infiltrated PMNs in postreperfusion cardiac tissue and adhering to coronary vasculature were significantly attenuated by the PKC-{zeta} peptide inhibitor. Hatched boxes represent non-PMN-perfused hearts, and solid boxes represent PMN-perfused hearts. **P < 0.01 from I/R + PMN. B: histological assessment of intravascular PMNs that adhered to the coronary vasculature in isolated perfused rat heart samples taken from 3 rats/group and 10 areas/heart. The numbers of PMNs adhering to the coronary vasculature were not significantly different from I/R + PMN. Hatched boxes represent non-PMN-perfused hearts, and solid boxes represent PMN-perfused hearts. All values are mean numbers of PMNs/mm2 heart area ± SE. **P < 0.01 from I/R + PMN.

 
PMN adherence to coronary vascular endothelium was also evaluated within the assessment of total intravascular and infiltrated PMNs. As seen in Fig. 4B, the number of adherent PMNs to the coronary endothelium was not significantly reduced in I/R + PMN + PKC-{zeta} peptide inhibitor (5 µM)-treated hearts (43 ± 10%, P < 0.06; Fig. 4B).

NO release from rat aortic endothelium was measured to determine whether PKC-{zeta} peptide inhibitor provides cardioprotection by a mechanism involving increased endothelial NO release. In Fig. 5, PKC-{zeta} peptide inhibitor-treated endothelium generated significantly more NO by 47 ± 2% (2.5 µM, P < 0.05), 54 ± 5% (5 µM, P < 0.01), and 91 ± 15% (15 µM, P < 0.01) compared with basal NO release. At 1 µM, NO release was not significantly different from basal NO release. Acetylcholine (200 nM) was used as a positive control in the NO assay and significantly increased NO release by 67 ± 4% (P < 0.01) compared with basal NO release. The eNOS inhibitor L-NAME was used as another control to decrease basal release of NO to zero. Both the acetylcholine and PKC-{zeta} peptide inhibitor-induced production of NO were completely inhibited by treating the endothelium with L-NAME (400 µM). To attribute the source of the NO to the endothelium, experiments with endothelium-removed (denuded) rat aortic segments were incubated with the PKC-{zeta} peptide inhibitor (5 µM) and were not different from L-NAME-treated segments.



View larger version (40K):
[in this window]
[in a new window]
  		Fig. 5. Measurement of nitric oxide (NO) release from rat aortic segments. Endothelial NO release was significantly increased from basal NO release in PKC-{zeta} peptide inhibitor-treated segments (2.5–15 µM) as well as those treated with acetylcholine (ACh, 200 nM). NO release was significantly reduced in both groups given 400 µM L-NAME and in endothelium-removed (denuded) segments. All values are expressed as means ± SE. Numbers at the bottom of the bars are numbers of separate experiments. *P < 0.05 and **P < 0.01 from basal values.

 
Another mechanism of the cardioprotective effects of PKC-{zeta} peptide inhibitor may be related to inhibition of superoxide release. The PKC-{zeta} peptide inhibitor significantly inhibited superoxide release by 33–82% (2.5–15 µM, P < 0.01) except at 1 µM, where there was no difference from suspensions of PMA-stimulated rat PMNs (Fig. 6). SOD (10 µg /ml) was used as a positive control in the superoxide assays and degraded superoxide release produced by the PMA-stimulated rat PMNs by 99% (P < 0.01; Fig. 6).



View larger version (20K):
[in this window]
[in a new window]
  		Fig. 6. Superoxide release from rat PMNs. Superoxide release was measured from 5 x 106 PMNs after phorbol 12-myristate 13-acetate (PMA, 15 nM) stimulation. SOD (10 µg/ml) was employed as a positive control. The change in absorbance ({Delta}absorbance) was measured 360 s after PMA addition (peak response). Superoxide release was significantly inhibited by the PKC-{zeta} peptide inhibitor. All values are means ± SE. Numbers at the bottom of the bars are numbers of separate experiments. **P < 0.01 from PMA.

 

   DISCUSSION
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
The major findings of this study were as follows: 1) I/R + PMN + PKC-{zeta} peptide inhibitor-treated rat hearts (5 µM) exerted maximal restoration of postreperfusion LVDP and +dP/dtmax and was associated with maximal attenuation of total intravascular PMN infiltration in postreperfused myocardium; 2) both of these effects were blocked in the presence of L-NAME, which was similar to I/R + PMN control hearts; 3) NO release in rat aortic segments was significantly increased by 54% in the presence of the PKC-{zeta} inhibitor (5 µM); 4) this effect was blocked by L-NAME and in denuded segments; and 5) PMA-stimulated PMN superoxide release was significantly inhibited by 40% in the presence of the PKC-{zeta} inhibitor (5 µM).

The PKC-{zeta} peptide inhibitor's cardioprotective effects were characterized by a dose-dependent significant restoration of postreperfusion LVDP and +dP/dtmax. In addition, the cardioprotective effects of the PKC-{zeta} peptide inhibitor were blocked by L-NAME, suggesting that some of the cardioprotective effects were mediated by a NO mechanism (21, 27, 41).

The cardioprotective effect by the PKC-{zeta} inhibitor was associated with attenuating the PMN-induced cardiac dysfunction in this model of I/R (29, 41, 42). Our previous study (29) showed that sham I/R hearts perfused with the same number of PMNs do not demonstrate induced cardiac contractile dysfunction and PMN infiltration into the myocardium and suggests that I/R is required to elicit an appropriate chemotactic stimulus for PMN infiltration and cardiac contractile dysfunction. In addition, perfusion of untreated I/R hearts without PMNs does not result in prolonged cardiac contractile dysfunction, indicating that global ischemia alone was not the cause of sustained contractile dysfunction in this model of I/R (25, 36, 42, 43). Furthermore, sham I/R hearts and I/R hearts treated with the PKC-{zeta} peptide inhibitor did not show a direct effect on cardiac contractile function, indicating that the PKC-{zeta} peptide inhibitor imparts no direct effect on cardiac contractile function at the highest dose used in this assay.

In contrast to our results regarding PMN-induced myocardial I/R injury, previous studies (3, 18) suggest that PMNs do not significantly contribute to cardiac contractile dysfunction after I/R. This may be due to differences in the duration of ischemia between their study (i.e., 15 min) (18) and our study (i.e., 20 min). In our model of I/R, 20 min of ischemia is the time period required to induce a sufficient chemotactic stimulus for PMN infiltration (15, 29, 42). Additionally, a longer duration of ischemia (i.e., 30 min) results in significant cardiac contractile dysfunction, hearts do not recover to initial LVDP values in the absence of PMN reperfusion, and it is not appropriate to attribute the I/R dysfunction to PMNs (15, 42).

In our ex vivo I/R model, cardioprotection may be provided by a significant reduction in PMN infiltration into postischemic cardiac tissue (29, 41–43). The PKC-{zeta} peptide inhibitor dose dependently inhibited PMN infiltration, and this effect was blocked by L-NAME. However, intravascular coronary adherence was similar among all of the doses tested and was not significantly different from the I/R + PMN group. The fact that the majority of PMNs (i.e., 70%) had transmigrated into the postreperfused tissue suggests that differences in PMN vascular adherence between I/R + PMN + PKC-{zeta} peptide inhibitor-treated hearts would conceivably be observed at earlier time points. Furthermore, the reduced proportion of adhered PMNs per millimeter squared compared with total PMNs per millimeter squared would require a larger difference (i.e., 60%) between the I/R + PMN and treatment groups to achieve statistical significance (29).

The cardiac function results were further supported by the NO release and superoxide release assay results. The PKC-{zeta} peptide inhibitor dose dependently augmented NO release from the rat aorta and inhibited PMN superoxide release. Furthermore, the source of stimulated NO release by the PKC-{zeta} peptide inhibitor can be attributed to the aortic endothelium, because denuded segments blocked NO release to the same extent as L-NAME-treated segments. Although there is no direct link between the in vitro assays (i.e., NO release) and I/R hearts, these results tend to parallel the cardiac function data except for the 15 µM dose. This dose was most effective at augmenting NO release and inhibiting superoxide release yet exerted cardiodepressent effects in non-PMN-perfused hearts. The negative effects observed in the isolated heart preparation may be due to differences in concentration sensitivity between a whole organ and isolated cells (e.g., PMNs) or vascular segments (e.g., aortic endothelium) (29).

During the early reperfusion period (5 min) of acute myocardial ischemia, PKC activation is enhanced (34). PKC activation inhibits eNOS; therefore, releasing the inhibition on this enzyme allows for an increase in NO production (14, 41). Previous studies (2, 17) have suggested that inhibition of the classical isoform PKC-{beta} attenuates vascular dysfunction in humans and animal models with Type 1 diabetes. However, the compound used in those studies inhibited both PKC-{beta}I and -{beta}II isoforms and was not selective for a specific isoform (17). In this study, the considerable increase in endothelial release of NO may be due to enhanced eNOS activity resulting from selective PKC-{zeta} inhibition (14). The doses of the PKC-{zeta} peptide inhibitor used in this study have been previously described to be specific for the PKC-{zeta} pseudosubstrate binding domain and do not cross-react with other PKC isoforms (7).

Activation of PKC-{zeta} is also associated with an increase in superoxide and hydrogen peroxide release from endothelial cells and PMNs (7, 10), suggesting that inhibition of superoxide release would enhance NO bioavailability (6). Previous studies (6, 28, 32) have shown that superoxide anion increases endothelial cell adhesion expression and quenches endogenous NO.

In this study, the PKC-{zeta} inhibitor attenuated the PMA-stimulated PMN superoxide response. A previous study (7) using the same type of PKC-{zeta} peptide inhibitor also showed 70% inhibition of the PMN superoxide response in a similar concentration range. However, the present results differ from the Dang et al. study in that the PMA-stimulated PMN superoxide response was inhibited in this study, whereas the N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP)-stimulated PMN superoxide response was inhibited in the Dang et al. study. This is most likely due to differences in the concentrations of PMA and fMLP used in the two studies.

Prior studies have associated PKC-{zeta} not only with PMN and endothelial cell superoxide release but also with PMN chemotaxis (7, 10, 19). Thus inhibition of PKC-{zeta} would attenuate PMN extravasation during the postreperfusion acute inflammatory response (41, 42).

In summary, these results show a cardioprotective effect on LVDP and +dP/dtmax by the selective PKC-{zeta} peptide inhibitor in the isolated perfused rat heart after I/R + PMNs. This cardioprotection appears to be related to attenuation of PMN infiltration into the myocardium along with an increase in endothelium-derived NO and inhibition of PMN-generated superoxide release. The net result would be attenuation cardiac contractile dysfunction in PMN-induced I/R injury.


   GRANTS
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This study was supported by National Heart, Lung, and Blood Institute Grant 1R15HL-76235-01. This study was also supported in part by the Philadelphia College of Osteopathic Medicine, Department of Pathology, Microbiology, and Immunology, and the Center for the Study of Chronic Diseases of Aging at Philadelphia College of Osteopathic Medicine (Philadelphia., PA).


   ACKNOWLEDGMENTS
 
The authors thank Taj-Jamal Andrews and Michael A. Hart (Philadelphia College of Osteopathic Medicine) for assistance with editing and formatting the revised manuscript, Bruce Stouch (Philadelphia College of Osteopathic Medicine) for assisting in the statistical analysis and comments, Dr. Peggy Stewart (Philadelphia College of Osteopathic Medicine) for assistance with the editing of the revised manuscript, and Dr. Margaret T. Weis (School of Pharmacy, Dept. of Pharmaceutical Sciences, Texas Tech University Health Sciences Center, Amarillo, TX) for assistance with the editing of the revised manuscript.


   FOOTNOTES
 

Address for reprint requests and other correspondence: L. H. Young, Dept. of Pathology, Microbiology, and Immunology, Philadelphia College of Osteopathic Medicine, 4170 City Ave., Philadelphia, PA 19131-1694 (E-mail: LindonYo{at}pcom.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Babior B. NADPH oxidase: an update. Blood 93: 1464–1476, 1999.[Free Full Text]
  2. Beckman JA, Goldfine AB, Gordon MB, Garrett LA, and Creager MA. Inhibition of protein kinase C beta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res 90: 107–111, 2002.[Abstract/Free Full Text]
  3. Bolli R. Role of neutrophils in myocardial stunning after brief ischaemia: the end of a six year old controversy (1987–1993). Cardiovasc Res 27: 728–730, 1993.[Web of Science][Medline]
  4. Buerke M, Weyrich AS, and Lefer AM. Isolated cardiac myocytes are sensitized by hypoxia-reoxygenation to neutrophil-released mediators. Am J Physiol Heart Circ Physiol 266: H128–H136, 1994.[Abstract/Free Full Text]
  5. Campbell B, Shin YK, Scalia R, and Lefer AM. Beneficial effects of N, N, N-trimethylsphingosine following ischemia and reperfusion in the isolated perfused rat heart. Cardiovasc Res 90: 393–400, 1998.
  6. Clancy RM, Leszczynska-Piziak J, and Abramson SB. Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action of NADPH oxidase. J Clin Invest 90: 1116–1121, 1992.[Web of Science][Medline]
  7. Dang PM, Fontayne A, Hakim J, El Benna J, and Perianin A. Protein kinase C {zeta} phosphorylates a subset of selective sites of the NAPDH oxidase component p47phox and participates in formyl peptide-mediated neutrophil respiratory burst. J Immunol 166: 1206–1213, 2001.[Abstract/Free Full Text]
  8. Dang PM, Rais S, Hakim J, and Perianin A. Redistribution of protein kinase C isoforms in human neutrophils stimulated by formyl peptides and phorbol myristate acetate. Biochem Biophys Res Commun 212: 664–672, 1995.[CrossRef][Web of Science][Medline]
  9. Dekker LV, Leitges M, Altschuler G, Mistry N, McDermott A, Roes J, and Segal A. Protein kinase C-{beta} contributes to NADPH oxidase activation in neutrophils. Biochem J 347: 285–289, 2000.
  10. Frey RS, Rahman A, Kefer JC, Minshall RD, and Malik AB. PKC {zeta} regulates TNF-{alpha}-induced activation of NADPH oxidase in endothelial cells. Circ Res 90: 1012–1019, 2002.[Abstract/Free Full Text]
  11. Gschwendt M, Dieterich S, Rennecke J, Kittstein W, Mueller HJ, and Johannes FJ. Inhibition of protein kinase C µ by various inhibitors. Differentiation from protein kinase C isoenzymes. FEBS Lett 392: 77–80, 1996.[CrossRef][Web of Science][Medline]
  12. Guo JP, Murohara T, Buerke M, Scalia R, and Lefer AM. Direct measurement of nitric oxide release from vascular endothelial cells. J Appl Physiol 81: 774–779, 1996.[Abstract/Free Full Text]
  13. Hansen PR. Role of neutrophils in myocardial ischemia and reperfusion. Circulation 91: 1872–1885, 1995.[Abstract/Free Full Text]
  14. Hirata K, Kuroda R, Sakoda T, Katayama M, Inuoue N, Suematsu M, Kawashima S, and Yokoyama M. Inhibition of endothelial nitric oxide synthase activity by protein kinase C. Hypertension 25: 180–185, 1995.[Abstract/Free Full Text]
  15. Ikeda Y, Young LH, Ross CR, and Lefer AM. PR-39, a proline/arginine-rich antimicrobial peptide, exerts cardioprotective effects in myocardial ischemia/reperfusion. Cardiovasc Res 49: 69–77, 2001.[Abstract/Free Full Text]
  16. Inagaki K, Hahn HS, Dorn GW II, and Mochly-Rosen D. Additive protection of the ischemic heart ex vivo by combined treatment with {delta}-protein kinase C inhibitor and {epsilon}-protein kinase C activator. Circulation 108: 869–875, 2003.[Abstract/Free Full Text]
  17. Ishii H, Jirousek MR, Daisuke K, Takage C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feemer EP, and King GL. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC {beta} inhibitor. Science 272: 728–730, 1996.[Abstract]
  18. Juneau CF, Ito BR, del-Balzo U, and Engler RL. Severe neutrophil depletion by leucocyte filters or cytotoxic drug does not improve recovery of contractile function in stunned porcine myocardium. Cardiovasc Res 27: 720–727, 1993.[Abstract/Free Full Text]
  19. Laudanna C, Mochly-Rosen D, Liron T, Constantin G, and Butcher EC. Evidence of {zeta}-PKC involvement in polymorphonuclear neutrophil integrin-dependent adhesion and chemotaxis. J Biol Chem 273: 30306–30315, 1998.[Abstract/Free Full Text]
  20. Lefer A and Hayward R. The Role of Nitric Oxide in Ischemia-Reperfusion: Contemporary Cardiology, edited by Loscalzo J and Vita JA. Totowa, NJ: Humana, 2000, p. 357–380.
  21. Lefer AM and Lefer DJ. The role of nitric oxide and cell adhesion molecules on the microcirculation in ischemia-reperfusion. Cardiovasc Res 32: 743–751, 1996.[CrossRef][Web of Science][Medline]
  22. Li Z, Jiang H, Xie W, Zhang Z, Smcka AV, and Wu D. Roles of PLC-{beta}2 and -{beta}3 and PI3K{gamma} in chemoattractant-mediated signal transduction. Science 287: 1046–1053, 2000.[Abstract/Free Full Text]
  23. Lucchesi B and Mullane K. Leukocytes and ischemia-induced myocardial injury. Annu Rev Pharmacol Toxicol 26: 2011–2024, 1986.
  24. Lucchesi B, Werns S, and Fantone J. The role of neutrophil and free radicals in ischemic myocardial injury. J Mol Cell Cardiol 21: 1241–1251, 1989.[CrossRef][Web of Science][Medline]
  25. Ma XL, Tsao PS, Viehman GE, and Lefer AM. Neutrophil-mediated vasoconstriction and endothelial dysfunction in low-flow perfusion-reperfusion cat coronary artery. Circ Res 69: 95–106, 1991.[Abstract/Free Full Text]
  26. Ma XL, Weyrich AS, Lefer DJ, and Lefer AM. Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. Circ Res 72: 403–412, 1993.[Abstract/Free Full Text]
  27. Pabla R, Buda A, Flynn D, Blesse S, Shin A, Curtis M, and Lefer D. Nitric oxide attenuates neutrophil-mediated myocardial contractile dysfunction after ischemia and reperfusion. Circ Res 78: 65–72, 1996.[Abstract/Free Full Text]
  28. Patel KD, Zimmerman GA, Prescott SM, McEver RP, and Mclintyre TM. Oxygen radicals induce human endothelial cells to express GMP-140 and bind neutrophils. J Cell Biol 112: 749–759, 1991.[Abstract/Free Full Text]
  29. Peterman EE, Taormina P II, Harvey M, and Young LH. Gö 6983 exerts cardioprotective effects in myocardial ischemia/reperfusion. J Cardiovasc Pharmacol 43: 645–656, 2004.[Web of Science][Medline]
  30. Rubanyi GM, Desiderio D, Luisi A, Johns A, and Sybertz EJ. Phobol dibutyrate inhibits release and action of endothelium-derived relaxing factor(s) in canine blood vessels. J Pharmacol Exp Ther 249: 858–863, 1989.[Abstract/Free Full Text]
  31. Rubanyi GM and Vanhoutte PM. Oxygen-derived free radicals, endothelium, and responsiveness of vascular smooth muscle. Am J Physiol Heart Circ Physiol 250: H815–H821, 1986.[Abstract/Free Full Text]
  32. Semb AG, Ytrehus K, Vaage J, Myklebust R, and Mjos OD. Functional impairment in isolated rat hearts induced by activated leukocytes: protective effect of oxygen free radical scavengers. J Mol Cell Cardiol 21: 877–887, 1989.[CrossRef][Web of Science][Medline]
  33. Shandelya SM, Kuppusamy P, Weisfeldt ML, and Zweier JL. Evaluation of the role of polymorphonuclear leukocytes on contractile function in myocardial reperfusion injury: evidence for plasma-mediated leukocyte activation. Circulation 87: 536–546, 1993.[Abstract/Free Full Text]
  34. Strasser RH, Braun-Dullaeus R, Walendzik H, and Marquetant R. {alpha}1-Receptor-independent activation of protein kinase C in acute myocardial ischemia. Circ Res 70: 1304–1312, 1992.[Abstract/Free Full Text]
  35. Tsao PS, Aoki N, Lefer DJ, Johnson G III, and Lefer AM. Time course of endothelial dysfunction and myocardial injury during myocardial ischemia and reperfusion in the cat. Circulation 82: 1402–1412, 1990.[Abstract/Free Full Text]
  36. Tsao PS and Lefer AM. Time course and mechanism of endothelial dysfunction in isolated ischemic- and hypoxic-perfused rat hearts. Am J Phyiol Heart Circ Physiol 259: H1660–H1666, 1990.
  37. Tsao PS, Ma XL, and Lefer AM. Activated neutrophils aggravate endothelial dysfunction after reperfusion of the ischemic feline myocardium. Am Heart J 123: 1464–1471, 1992.[CrossRef][Web of Science][Medline]
  38. Weiss S. Tissue destruction by neutrophils. N Engl J Med 320: 365–375, 1989.[Web of Science][Medline]
  39. Weyrich AS, Ma XL, and Lefer AM. Time course of coronary vascular endothelial adhesion molecule expression during reperfusion of the ischemic feline myocardium. J Leukoc Biol 57: 45–55, 1995.[Abstract]
  40. Xiao YQ, Minami K, Mue S, and Ohuchi K. Pharmacological analysis of protein kinases responsible for chemotaxis of rat peritoneal neutrophils. Eur J Pharmacol 360: 195–204, 1998.[CrossRef][Web of Science][Medline]
  41. Young LH, Ikeda Y, and Lefer AM. Caveolin-1 peptide exerts cardioprotective effects in myocardial ischemia-reperfusion via nitric oxide mechanism. Am J Physiol Heart Circ Physiol 280: H2489–H2495, 2001.[Abstract/Free Full Text]
  42. Young LH, Ikeda Y, and Lefer AM. Protein kinase inhibition exerts cardioprotective effects in myocardial ishemia/reperfusion via inhibition of superoxide release. Methods Find Exp Clin Pharmacol 23: 107–114, 2001.[CrossRef][Web of Science][Medline]
  43. Young LH, Ikeda Y, Scalia R, and Lefer AM. Wortmannin, a potent antineutrophil agent, exerts cardioprotective effects in myocardial ischemia/reperfusion. J Pharmacol Exp Ther 295: 37–43, 2000.[Abstract/Free Full Text]
  44. Zulueta JJ, Yu FS, Hertig IA, Thannickal VJ, and Hassoun PM. Release of hydrogen peroxide in response to hypoxia-reoxygenation: role of an NADPH oxidase-like enzyme in endothelial cell plasma membrane. Am J Respir Cell Mol Biol 12: 41–49, 1995.[Abstract]



This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. R. Ussher, J. S. Jaswal, C. S. Wagg, H. E. Armstrong, D. G. Lopaschuk, W. Keung, and G. D. Lopaschuk
Role of the atypical protein kinase C{zeta} in regulation of 5'-AMP-activated protein kinase in cardiac and skeletal muscle
Am J Physiol Endocrinol Metab, August 1, 2009; 297(2): E349 - E357.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Defer, A. Azroyan, F. Pecker, and C. Pavoine
TNFR1 and TNFR2 Signaling Interplay in Cardiac Myocytes
J. Biol. Chem., December 7, 2007; 282(49): 35564 - 35573.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
D. Guo, T. Nguyen, M. Ogbi, H. Tawfik, G. Ma, Q. Yu, R. W. Caldwell, and J. A. Johnson
Protein kinase C-{varepsilon} coimmunoprecipitates with cytochrome oxidase subunit IV and is associated with improved cytochrome-c oxidase activity and cardioprotection
Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2219 - H2230.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. Omiyi, R. J. Brue, P. Taormina II, M. Harvey, N. Atkinson, and L. H. Young
Protein Kinase C {beta}II Peptide Inhibitor Exerts Cardioprotective Effects in Rat Cardiac Ischemia/Reperfusion Injury
J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 542 - 551.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
289/2/H898    most recent
00883.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Phillipson, A.
Right arrow Articles by Young, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Phillipson, A.
Right arrow Articles by Young, L. H.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.